1. Search Result
Search Result
Results for "

RSL3

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

4

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100218A
    RSL3
    285+ Cited Publications

    (1S,3R)-RSL3

    p62 Glutathione Peroxidase Ferroptosis Reactive Oxygen Species Cancer
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    RSL3
  • HY-100218C

    Drug Isomer Ferroptosis Cancer
    (1R,3R)-RSL3 is an isomer of RSL3 (HY-100218A). RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    (1R,3R)-RSL3
  • HY-W015273A

    Endogenous Metabolite Ferroptosis Metabolic Disease Cancer
    Trans-3-Indoleacrylic acid is a tryptophan metabolite, which promotes tumor development through inhibition of RSL3 (HY-100218A) induced ferroptosis via AHR-ALDH1A3-FSP1-CoQ10 axis, and facilitates colorectal carcinogenesis
    trans-3-Indoleacrylic acid
  • HY-163074

    Ferroptosis Cancer
    Ferroptosis-IN-6 (compound 13) is a potent inhibitor of Ferroptosis with EC50 of 25.5 nM. Ferroptosis-IN-6 significantly inhibits RSL3-induced cell death in cells and in vivo .
    Ferroptosis-IN-6
  • HY-169375

    Ligands for Target Protein for PROTAC Cancer
    RSL3-4-Me is the active control of the target protein ligand Demethyl-RSL3 (HY-135832), which can be used for the synthesis of PROTAC .
    RSL3-4-Me
  • HY-100218B

    Glutathione Peroxidase Ferroptosis Cancer
    (1R,3S)-RSL3 is the less active (1R,3S)-enantiomer of RSL3 ((1S,3R)-RSL3). (1R,3S)-RSL3 and RSL3 induce cell death in HT22 wild-type cells with EC50 values of 5.2 µM and 0.004 µM, rspectively .
    (1R,3S)-RSL3
  • HY-135832

    Ligands for Target Protein for PROTAC Cancer
    Demethyl-RSL3 is a ligand for target protein for pROTAC.
    Demethyl-RSL3
  • HY-161931

    Ligands for Target Protein for PROTAC Cancer
    Demethyl-RSL3-boc is a ligand for target protein for pROTAC.
    Demethyl-RSL3-boc
  • HY-155952

    Glutathione Peroxidase Cancer
    LOC1886 is a covalent inhibitor of GPX4 with slightly lower potency than RSL3 and ML162 .
    LOC1886
  • HY-167888

    Ferroptosis Glutathione Peroxidase Cancer
    NPD4928, a GPX4 inhibitor, enhances RSL3 (HY-100218A)-dependent ferroptosis. NPD4928 binds to ferroptosis suppressor protein 1 (FSP1) and inhibits its enzymatic activity .
    NPD4928
  • HY-168768

    Ferroptosis Lipoxygenase Cancer
    FerroLOXIN-1 is a potent inhibitor of 15LOX-2 that selectively blocked production of pro-ferroptotic HOO-ETE-PE and protected against RSL3-induced ferroptosis. FerroLOXIN-1 closely interacted therein with 15LOX-2 only, and in particular with Y154, N155, W158 .
    FerroLOXIN-1
  • HY-136057
    iFSP1
    15+ Cited Publications

    Ferroptosis Cancer
    iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1) (AIFM2) with an EC50 of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout cells which overexpressed FSP1. iFSP1 is able to sensitize a variety of human cancer cell lines to the ferroptosis inducer, such as (1S,3R)-RSL3 (HY-100218A) .
    iFSP1
  • HY-149670

    Ferroptosis Inflammation/Immunology
    Ferroptosis-IN-3 (Compound 25) is a ferroptosis inhibitor. Ferroptosis-IN-3 inhibits RSL3-induced ferroptosis (EC50: 8.6?nM in HT-1080?cells). Ferroptosis-IN-3 scavenges DPPH and ABTS radicals (EC50: 3.94?and 6.3 μM respectively). Ferroptosis-IN-3 decreases lipid peroxidation .
    Ferroptosis-IN-3
  • HY-155075

    PROTACs Glutathione Peroxidase Ferroptosis Cancer
    NC-R17 is a PROTAC-class, non-covalent GPX4 degrader based on RSL3, involved in ferroptosis. NC-R17 has antitumor activity and is used for non-covalent GPX4 PROTAC design . NC-R17 consists of a target protein ligand (red part) Demethyl-RSL3 (HY-135832); an E3 ubiquitin ligase ligand (blue part) Lenalidomide (HY-A0003) and a PROTAC linker (black part) (HY-169376). E3 ubiquitin ligase and linker can form Lenalidomide-C13-piperazine-Boc (HY-169377) .
    NC-R17
  • HY-170959

    Ferroptosis Neurological Disease Metabolic Disease
    NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC50s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .
    NYY-6a
  • HY-115701

    1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-phosphoethanolamine; 15(S)-HpETE-SAPE; 15(S)-hydroperoxyeicostetraenoic acid-SAPE

    Ferroptosis Inflammation/Immunology
    1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe is a phospholipid that contains stearic acid (HY-B2219) at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-Pe (SAPE) by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe (0.6 and 0.9 μM) increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.
    1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe
  • HY-153368

    KT-413

    IRAK PROTACs Cancer
    KT-413 (example I-3) is an orally active PROTAC-class IRAK degrader . KT-413 consists of a target protein ligand (red part) PROTAC IRAK4 ligand-5 (HY-168311), an E3 ubiquitin ligase ligand (blue part) Thalidomide-4-Br (HY-W039116), and a PROTAC linker (black part) 2-(2-Azaspiro[3.3]heptan-6-yl)ethanamine (HY-168313). E3 ubiquitin ligase and linker can form Thalidomide-NH-C2-2-azaspiro[3.3]heptane (HY-168312). The active control for the target protein ligand is RSL3-4-Me (HY-169375).
    Zomiradomide
  • HY-169298

    Ferroptosis Cancer
    Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC50s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .
    Ferroptosis-IN-15
  • HY-162106

    Ferroptosis PROTACs Glutathione Peroxidase Cancer
    PROTAC GPX4 degrader-2 (compound 18a) is a proteolysis targeting chimeras (PROTACs) that can degrade glutathione peroxidase 4 (GPX4), with the DC50, 48h value of 1.68 μM. PROTAC GPX4 degrader-2 induces the accumulation of lipid peroxides and mitochondrial depolarization, subsequently triggering ferroptosis. PROTAC GPX4 degrader-2 has anti-proliferative effect .
    PROTAC GPX4 degrader-2
  • HY-W015273AR

    Endogenous Metabolite Ferroptosis Metabolic Disease Cancer
    trans-3-Indoleacrylic acid (Standard)
  • HY-B1465R

    Endogenous Metabolite Others
    1-Hexadecanol (Standard) is the analytical standard of 1-Hexadecanol. This product is intended for research and analytical applications. 1-Hexadecanol is a fatty alcohol, a lipophilic substrate. 1-Hexadecanol can be used for the research of ferroptosis .
    1-Hexadecanol (Standard)
  • HY-B1465

    Palmityl alcohol

    Endogenous Metabolite Others
    1-Hexadecanol is a fatty alcohol, a lipophilic substrate. 1-Hexadecanol can be used for the research of ferroptosis .
    1-Hexadecanol
  • HY-162812

    Apoptosis Cholinesterase (ChE) Tau Protein Ferroptosis Histamine Receptor Neurological Disease
    H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC50 of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ1-42 induced by itself and Cu 2+ (95.48% and 88.63%) , and degraded the Aβ1-42 fibrils induced by itself and Cu 2+ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu 2+, Zn 2+, Al 3+, and Fe 2+. H3R antagonist 4 significantly reduced tau protein hyperphosphorylation induced by Aβ1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .
    H3R antagonist 4
  • HY-163654

    Ferroptosis Cancer
    Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis .
    Ferroptosis-IN-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: